Focus on Biosimilars Xbrane's specialization in high demand biosimilars and long-acting injectables presents significant opportunities to supply complementary insights or technologies that enhance biosimilar development and commercialization strategies.
Recent Asset Sale The sale of R&D assets to Alvotech for approximately $28.9 million indicates potential openings for collaboration or licensing agreements with Xbrane to co-develop or commercialize biosimilars in different markets.
Financial Support & Investment With a recent short-term loan of SEK 20 million from its main shareholder, Systematic Group, there is ongoing investor confidence that could facilitate partnerships or funding of joint research initiatives to accelerate product pipeline growth.
Pipeline Development Xbrane's ongoing development of biosimilars such as Nivolumab referencing Opdivo and its focus on controlled-release drugs suggest opportunities to provide manufacturing, formulation, or regulatory consulting services to expedite clinical trials and product registration.
Strategic Collaborations The licensing agreement with Intas and the focus on developing biosimilars present avenues to propose value-added services like market analysis, regulatory navigation, or sales distribution channels in key global regions to maximize commercial reach.
Xbrane Biopharma AB uses 8 technology products and services including Microsoft 365, Font Awesome, TweenMax, and more. Explore Xbrane Biopharma AB's tech stack below.
| Xbrane Biopharma AB Email Formats | Percentage |
| First.Last@xbrane.com | 45% |
| First@xbrane.com | 5% |
| First.Last@xbrane.com | 45% |
| First@xbrane.com | 5% |
Biotechnology ResearchSweden51-200 Employees
Xbrane is a biopharmaceutical company specialized in high demand biosimilars and long acting injectables. We enable global health equality by bringing affordable drugs to treat underserved people suffering from critical diseases. Xbrane posses world leading expertise in developing true generics for injectable controlled release drugs and proprietary high-yield protein expression technology.
Company Overview
Media & News
Funding & FinancialsXbrane Biopharma AB has raised a total of $1.8M of funding over 1 rounds. Their latest funding round was raised on Dec 02, 2024 in the amount of $1.8M.
Xbrane Biopharma AB's revenue is estimated to be in the range of $1M
Funding & FinancialsXbrane Biopharma AB has raised a total of $1.8M of funding over 1 rounds. Their latest funding round was raised on Dec 02, 2024 in the amount of $1.8M.
Xbrane Biopharma AB's revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com